Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Intra-Cellular Therapies, Inc. | d639865dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9, 2013
Intra-Cellular Therapies, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 000-54896
Delaware | 36-4742850 | |
(State or other jurisdiction of incorporation) |
(IRS Employer Identification No.) |
3960 Broadway
New York, New York 10032
(Address of principal executive offices, including zip code)
(212) 923-3344
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 8.01 | Other Events. |
On December 9, 2013, Intra-Cellular Therapies, Inc. issued a press release announcing positive topline results from the Phase 2 clinical trial of its lead drug candidate, ITI-007, in patients with acutely exacerbated schizophrenia. In this study, ITI-007 met the trials pre-specified primary endpoint, improving symptoms associated with schizophrenia as measured by a statistically significant and clinically meaningful decrease in the Positive and Negative Syndrome Scale (PANSS) total score. The trial also met key secondary outcome measures related to efficacy on PANSS subscales and safety.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 9.01 | Financial Statements and Exhibits. |
(d) | The following exhibit is filed with this report: |
Exhibit Number |
Description | |
99.1 | Press Release dated December 9, 2013. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTRA-CELLULAR THERAPIES, INC. | ||
By: | /s/ Sharon Mates, Ph.D. | |
Sharon Mates, Ph.D. | ||
President and Chief Executive Officer |
Date: December 9, 2013
3